drugset / Trial / NCT00119314
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Phase 2
Withdrawn
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin.
Timeline
- Start
- 2004-07
- Primary completion
- 2005-07
- Completion
- 2005-07
Outcome
Outcome not reported
Stopped (Enrollment): “slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |